Trial Profile
Does gefitinib prolong the survival of adenocarcinoma patients against non-adeno non-small cell lung cancer? A retrospective study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Sep 2013 New trial record